- Home
- TTI vs AVXL Comparison
TTI vs AVXL Comparison
Compare TTI & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTI
- AVXL
- Stock Information
- Founded
- TTI 1981
- AVXL 2004
- Country
- TTI United States
- AVXL United States
- Employees
- TTI N/A
- AVXL N/A
- Industry
- TTI Oil & Gas Production
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TTI Energy
- AVXL Health Care
- Exchange
- TTI Nasdaq
- AVXL Nasdaq
- Market Cap
- TTI 761.0M
- AVXL 684.6M
- IPO Year
- TTI 1990
- AVXL N/A
- Fundamental
- Price
- TTI $7.17
- AVXL $7.74
- Analyst Decision
- TTI Strong Buy
- AVXL Strong Buy
- Analyst Count
- TTI 3
- AVXL 3
- Target Price
- TTI $7.00
- AVXL $44.00
- AVG Volume (30 Days)
- TTI 3.9M
- AVXL 1.3M
- Earning Date
- TTI 10-28-2025
- AVXL 12-22-2025
- Dividend Yield
- TTI N/A
- AVXL N/A
- EPS Growth
- TTI 7085.43
- AVXL N/A
- EPS
- TTI 0.92
- AVXL N/A
- Revenue
- TTI $618,755,000.00
- AVXL N/A
- Revenue This Year
- TTI $3.84
- AVXL N/A
- Revenue Next Year
- TTI $4.07
- AVXL N/A
- P/E Ratio
- TTI $7.85
- AVXL N/A
- Revenue Growth
- TTI 0.17
- AVXL N/A
- 52 Week Low
- TTI $2.03
- AVXL $6.62
- 52 Week High
- TTI $8.20
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- TTI 57.09
- AVXL 30.83
- Support Level
- TTI $6.70
- AVXL $7.88
- Resistance Level
- TTI $7.99
- AVXL $8.35
- Average True Range (ATR)
- TTI 0.48
- AVXL 0.42
- MACD
- TTI -0.10
- AVXL -0.13
- Stochastic Oscillator
- TTI 31.10
- AVXL 13.30
About TTI Tetra Technologies Inc.
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments namely Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. Majority of revenue is from Completion Fluids & Products. The company derives maximum revenue from United states.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.